Aspen Grants Share Awards to Top Executives
Directors and prescribed officers received deferred incentive shares priced at R161.73 under the Aspen Management Deferred Incentive Scheme.
Updated on Nov. 9, 2026 in Business Strategy

Aspen Pharmacare Holdings Limited granted deferred incentive shares to its directors, prescribed officers, and company secretaries on 4 and 5 November 2026. The awards were made off-market at a grant price of R161.73 per share and vest over three, four, and five years.
Why it matters
The grants tie executive compensation to the company's share price over a multi-year period, aligning senior leaders' financial interests with long-term shareholder value. The disclosure was made under the JSE Listings Requirements, which require transparency on director dealings.
Stephen Saad's 64,797-share award carries a deemed value of R10,479,456.82, while Karen Naidoo's 1,776-share award is valued at R287,228.04. The filing does not disclose the total share count granted across all recipients.
The players
Aspen Pharmacare Holdings Limited
Aspen is a South African pharmaceutical company listed on the Johannesburg Stock Exchange and one of the largest drug manufacturers on the African continent.
Stephen Bradley Saad
Saad is an executive at Aspen and received the largest share award in this grant, worth a deemed R10.48 million.
Sean Matthew Capazorio
Capazorio is an Aspen director who received 29,726 deferred incentive ordinary shares in the November 2026 grant.
The details
Awards were made to six recipients, with deferred incentive ordinary shares going to Saad, Capazorio, and Hill, and deferred incentive bonus shares to Khan and Naidoo, with Heinz Schütte receiving deferred incentive shares. The grant price is based on the 3-day volume-weighted average price on 2 November 2026, and the awards were made under the Aspen Management Deferred Incentive Scheme.
Timeline
2 November 2026: Reference date for the 3-day VWAP used to set the grant price.
4 November 2026: Awards granted to Sean Capazorio, Lorraine Hill, and Raeesa Khan.
5 November 2026: Awards granted to Stephen Saad, Heinz Schütte, and Karen Naidoo.
9 November 2026: Announcement published on SENS.
Market Landscape
The grants are made under a deferred incentive scheme that vests across three to five years, a structure common among South African listed companies seeking to retain senior talent. Under the JSE Listings Requirements, such off-market dealings by directors must be publicly disclosed, which this SENS announcement fulfils.
For shareholders, the vesting schedule means the value of these awards depends on Aspen's share price over the next three to five years. For the broader market, the disclosure gives investors visibility into how senior executives are being rewarded.
The takeaway
Investors tracking Aspen should watch the share price through 2029 to 2031, when these deferred awards vest and determine the real value received by recipients. Director dealings filings like this one are a useful signal of how management is compensated relative to company performance.
Further reading
For related coverage, see Business Strategy on South African corporate decision-making.
Source note: This article includes information reported by Ghanamma.






